The methodological approach to the ivermectin meta-analysis provides further reassurance of the robustness of the findings. Mr Andrew Bryant and Dr Edmund Fordham describe some of the critical… read more.
The Bryant-Lawrie meta-analysis included only randomised controlled trials (RCTs) but evidence from observational trials and real world experience sheds further light on the effectiveness of ivermectin, according to… read more.
June 2021 saw the publication of the systematic review and meta-analysis of randomised controlled trials of ivermectin for treatment and prophylaxis of covid-19 undertaken by Dr Tess Lawrie’s… read more.
AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy…. read more.
Rates of the very rare clotting disorder, thrombosis with thrombocytopenia syndrome (TTS), following a second dose of Vaxzevria are comparable to the background rate in an unvaccinated population… read more.
Aspirin appears to reduce cardiovascular events in patients with pneumonia, researchers reported on July 7, 2021 at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Investigator… read more.
Investigations carried out at the La Jolla institute for Immunology (LJI) Show that the combination of vitamin C and TET proteins are essential for the proper function of… read more.
Interim results from a Phase 1/IIa sub-study published in the New England Journal of Medicine (NEJM) demonstrated that both humoral (antibody) and cellular (T-cell) immune responses generated by… read more.
Gilead Sciences, Inc. announced a pooled analysis of a 48-week open-label extension of two Phase III studies (Study 1489 and Study 1490) shows 99% of participants who initiated… read more.
Takeda Pharmaceutical announced results from two final analyses from the Phase III HELP (Hereditary Angioedema Long-term Prophylaxis) Study Open-label Extension (OLE), which evaluated the long-term safety (primary endpoint)… read more.
Incyte announced that positive data from the Phase III REACH3 study have been published in The New England Journal of Medicine (NEJM) demonstrating that treatment with ruxolitinib (Jakafi)… read more.
University of California – San Diego In mouse models of human disease, immunotoxins targeting the protein mesothelin prevent liver cells from producing collagen, a precursor to fibrosis and… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
